Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder

Author:

Vigo DanielORCID,Haro Josep Maria,Hwang Irving,Aguilar-Gaxiola Sergio,Alonso Jordi,Borges Guilherme,Bruffaerts Ronny,Caldas-de-Almeida Jose Miguel,de Girolamo Giovanni,Florescu Silvia,Gureje Oye,Karam Elie,Karam Georges,Kovess-Masfety Viviane,Lee Sing,Navarro-Mateu Fernando,Ojagbemi Akin,Posada-Villa Jose,Sampson Nancy A.,Scott Kate,Stagnaro Juan Carlos,ten Have Margreet,Viana Maria Carmen,Wu Chi-Shin,Chatterji Somnath,Cuijpers Pim,Thornicroft Graham,Kessler Ronald C.ORCID

Abstract

Abstract Background Major depressive disorder (MDD) is a leading cause of morbidity and mortality. Shortfalls in treatment quantity and quality are well-established, but the specific gaps in pharmacotherapy and psychotherapy are poorly understood. This paper analyzes the gap in treatment coverage for MDD and identifies critical bottlenecks. Methods Seventeen surveys were conducted across 15 countries by the World Health Organization-World Mental Health Surveys Initiative. Of 35 012 respondents, 3341 met DSM-IV criteria for 12-month MDD. The following components of effective treatment coverage were analyzed: (a) any mental health service utilization; (b) adequate pharmacotherapy; (c) adequate psychotherapy; and (d) adequate severity-specific combination of both. Results MDD prevalence was 4.8% (s.e., 0.2). A total of 41.8% (s.e., 1.1) received any mental health services, 23.2% (s.e., 1.5) of which was deemed effective. This 90% gap in effective treatment is due to lack of utilization (58%) and inadequate quality or adherence (32%). Critical bottlenecks are underutilization of psychotherapy (26 percentage-points reduction in coverage), underutilization of psychopharmacology (13-point reduction), inadequate physician monitoring (13-point reduction), and inadequate drug-type (10-point reduction). High-income countries double low-income countries in any mental health service utilization, adequate pharmacotherapy, adequate psychotherapy, and adequate combination of both. Severe cases are more likely than mild-moderate cases to receive either adequate pharmacotherapy or psychotherapy, but less likely to receive an adequate combination. Conclusions Decision-makers need to increase the utilization and quality of pharmacotherapy and psychotherapy. Innovations such as telehealth for training and supervision plus non-specialist or community resources to deliver pharmacotherapy and psychotherapy could address these bottlenecks.

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Applied Psychology

Reference47 articles.

1. Compliance with medication regimens for mental and physical disorders;Cramer;Psychiatric Services,1998

2. Beyond utilization: Measuring effective coverage of obstetric care along the quality cascade;Larson;International Journal of Quality in Health Care,2017

3. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative;Merikangas;Archives of General Psychiatry,2011

4. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI);Kessler;International Journal of Methods in Psychiatric Research,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3